Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Vivus Inc (VVUS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 49,797
  • Shares Outstanding, K 105,950
  • Annual Sales, $ 124,260 K
  • Annual Income, $ 23,300 K
  • 36-Month Beta 0.80
  • Price/Sales 0.37
  • Price/Cash Flow 1.13
  • Price/Book N/A
  • Price/Earnings ttm 1.40
  • Earnings Per Share ttm 0.34
  • Most Recent Earnings -0.06 on 11/07/17
  • Next Earnings Date 03/14/18
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.45 +5.56%
on 01/18/18
0.55 -13.64%
on 01/04/18
-0.03 (-6.86%)
since 12/19/17
3-Month
0.45 +5.56%
on 01/18/18
0.83 -42.77%
on 10/20/17
-0.33 (-40.63%)
since 10/19/17
52-Week
0.45 +5.56%
on 01/18/18
1.38 -65.58%
on 06/07/17
-0.68 (-59.05%)
since 01/19/17

Most Recent Stories

More News
Free Research Reports on These Biotech Stocks -- Spectrum Pharma, Teligent, Vertex Pharma, and VIVUS

WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on SPPI, TLGT, VRTX, and VVUS which can be accessed for free by signing up to www.wallstequities.com/registration....

SPPI : 19.03 (+1.06%)
TLGT : 3.48 (-1.42%)
VVUS : 0.47 (unch)
VRTX : 157.97 (+0.50%)
Orexigen Struggles as Contrave Commercialization Costs Rise

Orexigen (OREX) hurt by higher commercialization costs related to Contrave.

OREX : 1.17 (+0.86%)
NVO : 57.79 (+2.27%)
VVUS : 0.47 (unch)
ARNA : 35.60 (+4.34%)
VIVUS Announces Change in Leadership

Board Member Thomas B. King appointed interim CEO; Seth Fischer steps down as CEO effective December 31, 2017

VVUS : 0.47 (unch)
VIVUS (VVUS) Q3 Loss Narrows, Qsymia Falters, Shares Down

VIVUS (VVUS) reported third-quarter results wherein it reported narrower-than- expected loss. However, Qsymia sales fell from the year-ago period.

VVUS : 0.47 (unch)
RDY : 38.67 (+1.02%)
EXEL : 28.00 (+0.50%)
TEVA : 20.70 (-0.05%)
VIVUS Reports Third Quarter 2017 Financial Results

CAMPBELL, CA--(Marketwired - November 07, 2017) - VIVUS, Inc. (NASDAQ: VVUS) (the "Company"), a biopharmaceutical company committed to the development and commercialization of innovative therapies focusing...

VVUS : 0.47 (unch)
VIVUS Reports Third Quarter 2017 Financial Results

CAMPBELL, CA--(Marketwired - November 07, 2017) - VIVUS, Inc. (NASDAQ: VVUS) (the "Company"), a biopharmaceutical company committed to the development and commercialization of innovative therapies focusing...

VVUS : 0.47 (unch)
VIVUS, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / November 7, 2017 / VIVUS, Inc. (NASDAQ: VVUS) will be discussing their earnings results in their Q3 Earnings Call to be held on November 7, 2017 at 4:30 PM Eastern Time.

VVUS : 0.47 (unch)
VIVUS Completes Tacrolimus Pre-IND Meeting With FDA

Company on track to initiate clinical trials in 2018

VVUS : 0.47 (unch)
VIVUS Completes Tacrolimus Pre-IND Meeting With FDA

Company on track to initiate clinical trials in 2018

VVUS : 0.47 (unch)
VIVUS to Host Third Quarter Business Update and Financial Results Conference Call on Tuesday, November 7, 2017

CAMPBELL, CA--(Marketwired - October 31, 2017) - VIVUS, Inc. (NASDAQ: VVUS) today announced that it will report financial results and provide a business update for the third quarter of 2017 after the...

VVUS : 0.47 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More

Business Summary

VIVUS is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes and sexual health. The company's lead investigational product in clinical development, Qnexa(TM), is expected to complete Phase 3 clinical trials for the treatment of obesity...

See More

Key Turning Points

2nd Resistance Point 0.50
1st Resistance Point 0.49
Last Price 0.47
1st Support Level 0.47
2nd Support Level 0.46

See More

52-Week High 1.38
Fibonacci 61.8% 1.02
Fibonacci 50% 0.91
Fibonacci 38.2% 0.81
Last Price 0.47
52-Week Low 0.45

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.